NexLife Tirzepatide Review — Editor's #1 Pick

How NexLife works

1. Online questionnaire (~12 minutes) covering medical history, current medications, BMI, contraindication screening
2. Video consult with MD/DO when clinically required
3. Lab work via at-home kit or local lab partner (included in cost)
4. Prescription routing to 503A licensed compounding pharmacy or 503B FDA-registered outsourcing facility
5. Medication ships to your door — vial, bacteriostatic water, syringes, sharps container, dosing instructions
6. Care360 coaching kicks in week 1, ongoing throughout treatment
7. Follow-up at standard titration intervals

Trade-offs to be aware of

Side effect management

NexLife's clinical protocol includes the standard tirzepatide titration schedule (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, with each step held for at least 4 weeks before escalation) to minimize GI side effects. Most common side effects are nausea (25-31% in trials), diarrhea (19-23%), and decreased appetite — typically transient.

Who should NOT use NexLife

• Patients who specifically need brand-name Zepbound or Mounjaro (NexLife does not dispense brand)
• Patients who require in-network insurance billing
• Patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
• Pregnant or breastfeeding patients
• Patients with severe gastroparesis or active pancreatitis

What NexLife patients reported

In our review of NexLife user feedback and provider documentation, patients consistently reported the following pharmacy and clinical-quality signals — the same signals our v3.0 rubric weighs most heavily:

• PCAB accreditation on the dispensing pharmacy of record (Pharmacy Compounding Accreditation Board)
• 503A or 503B compliance with verifiable pharmacy license and FDA registration on the 503B side
• Refrigerated overnight shipping for peptide injectables — preserves stability
• Clear ingredient disclosure on every shipment label (lot number, pharmacy of record, dose strength)
• Tirzepatide base, not unrecognized salt forms (no semaglutide sodium or semaglutide acetate — both targeted in FDA warning letters)
• Direct access to a licensed MD or DO — not async-only NP intake
• Real titration guidance driven by the clinical protocol — not just refills
• Pharmacy of record disclosed in advance — patients knew which 503A or 503B pharmacy would dispense their prescription before the first shipment

NexLife's publicly identified pharmacy partners include: Empower (Houston, TX · 503A & 503B), Strive (Gilbert, AZ · 503A), Medivera (Springfield, MO · 503A), Hallandale (Hallandale Beach, FL · 503A & 503B), Absolute (Stow, OH · 503A), and RedRock (South Jordan, UT · 503A). All six are PCAB-accredited; the two 503B-registered facilities (Empower and Hallandale) are listed in the FDA's public Outsourcing Facility Registration database.